Tesamorelin

Egrifta · Egrifta SV

Peptide peptide SubQ FDA/EMA Label

Half-life

26 min

Time to Peak

9 min

Steady State

~1 days

Dose Range

1–2 mg

Frequency

Daily

Overview

FDA-approved synthetic GHRH analog indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Increasingly used off-label for body composition optimization. Well-characterized PK profile from FDA approval studies. Supplied as lyophilized powder requiring reconstitution with sterile water (provided in kit).

Mechanism of Action

Binds GHRH receptors on pituitary somatotroph cells. Stimulates GH synthesis and secretion in a pulsatile, physiological manner. Reduces visceral adipose tissue.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Subcutaneous (SubQ)	1–2 mg	26 min	9 min	Daily

Storage & Handling

2-8C — Store refrigerated. Reconstitute with provided sterile water. Use immediately after reconstitution.

Used in Regimens

1 regimen

Tesamorelin — Visceral Fat Reduction

Tesamorelin GHRH analogue for visceral fat reduction and body recomposition. FDA-approved for HIV-associated lipodystrophy; widely used off-label in anti-ageing communities. The only GHRH peptide with Phase III RCT data showing significant visceral fat reduction.

Off-label anti-ageing protocol 1–2mg/day SubQ abdomen.

26wk peptide

Primary

Data Sources

FDA Label Egrifta SV (Tesamorelin) FDA Prescribing Information

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Tesamorelin with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.